Finance
Merck KGaA says high asset prices call for prudent M&A approach
Published by Global Banking and Finance Review
Posted on January 23, 2025
1 min readLast updated: January 27, 2026
Global Banking and Finance Review
Company
Published by Global Banking and Finance Review
Posted on January 23, 2025
1 min readLast updated: January 27, 2026
Merck KGaA's CEO highlights a cautious M&A approach due to high asset prices, focusing on organic growth and strengthening the Life Science unit.
DAVOS, Switzerland (Reuters) - The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
"We need to stay prudent and patient because our business is returning to growth organically. We are not in a rush," CEO Belen Garijo told Reuters in an interview on the sidelines of the World Economic Forum's annual meeting in Davos, Switzerland.
Merck is focused in particular on strengthening its Life Science unit, a maker of lab gear and supplies, but asset prices when measured as a multiple of earnings are high, she added.
(Reporting by Divya Chowdhury in Davos; Writing by Ludwig Burger; Editing by Friederike Heine)
The main topic is Merck KGaA's cautious M&A strategy due to high asset prices, focusing on organic growth.
Merck KGaA is cautious about M&A because asset prices are high, and they are focusing on organic growth.
Merck KGaA is focusing on strengthening its Life Science unit and achieving organic growth.
Explore more articles in the Finance category
